$ARTH
Arch Therapeutics, Inc.

2019 Q2 Form 10-Q Financial Statement

#000114420419025993 Filed on May 14, 2019

View on sec.gov

Income Statement

Concept 2019 Q2 2019 Q1 2018 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $933.6K $878.6K $1.179M
YoY Change -5.7% -12.14% 17.86%
% of Gross Profit
Research & Development $638.7K $628.8K $589.2K
YoY Change 0.74% -38.02% 1.44%
% of Gross Profit
Depreciation & Amortization $2.760K $1.780K $1.781K
YoY Change 61.78% 57.52% 145.99%
% of Gross Profit
Operating Expenses $1.572M $1.507M $1.768M
YoY Change -2.95% -25.15% 11.72%
Operating Profit -$1.507M -$1.768M
YoY Change -25.15% 11.72%
Interest Expense $283.1K $1.677M -$832.4K
YoY Change 264.64%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$1.289M $170.0K -$2.600M
YoY Change -41.67% -110.89% -766.73%
Income Tax
% Of Pretax Income
Net Earnings -$1.289M $170.0K -$2.600M
YoY Change -41.74% -110.93% -768.14%
Net Earnings / Revenue
Basic Earnings Per Share $0.00 -$0.02
Diluted Earnings Per Share -$7.656K $0.00 -$0.02
COMMON SHARES
Basic Shares Outstanding 173.6M 163.3M 161.1M shares
Diluted Shares Outstanding 168.6M 161.1M shares

Balance Sheet

Concept 2019 Q2 2019 Q1 2018 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $3.182M $1.956M $3.378M
YoY Change -50.97% -42.12% -31.9%
Cash & Equivalents $1.956M $3.378M
Short-Term Investments
Other Short-Term Assets $594.5K $453.1K $240.0K
YoY Change 560.58% 547.24% 242.87%
Inventory $0.00
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $3.776M $2.409M $3.618M
YoY Change -42.58% -30.16% -28.07%
LONG-TERM ASSETS
Property, Plant & Equipment $10.94K $13.70K $15.48K
YoY Change -42.79% -31.5% 55.94%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $3.500K $3.500K $3.500K
YoY Change 0.0% 0.0% 0.0%
Total Long-Term Assets $14.45K $17.20K $18.98K
YoY Change -36.12% -14.0% 41.36%
TOTAL ASSETS
Total Short-Term Assets $3.776M $2.409M $3.618M
Total Long-Term Assets $14.45K $17.20K $18.98K
Total Assets $3.791M $2.427M $3.637M
YoY Change -42.56% -30.07% -27.89%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $128.7K $175.6K $130.6K
YoY Change -29.74% -45.12% -54.84%
Accrued Expenses $141.8K $105.0K $145.9K
YoY Change -21.23% 50.03% -18.93%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $270.5K $280.6K $276.6K
YoY Change -24.62% -28.04% -41.22%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $3.692M $2.347M $4.024M
YoY Change -7.47% 134.68% 175.63%
Total Long-Term Liabilities $3.692M $2.347M $4.024M
YoY Change -7.47% 134.68% 175.91%
TOTAL LIABILITIES
Total Short-Term Liabilities $270.5K $280.6K $276.6K
Total Long-Term Liabilities $3.692M $2.347M $4.024M
Total Liabilities $3.962M $2.627M $4.301M
YoY Change -8.89% 89.03% 122.95%
SHAREHOLDERS EQUITY
Retained Earnings -$36.75M -$36.92M
YoY Change 26.8%
Common Stock $36.55M $36.25M
YoY Change 12.49%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$171.5K -$200.9K -$664.1K
YoY Change
Total Liabilities & Shareholders Equity $3.791M $2.427M $3.637M
YoY Change -42.56% -30.07% -27.89%

Cashflow Statement

Concept 2019 Q2 2019 Q1 2018 Q4
OPERATING ACTIVITIES
Net Income -$1.289M $170.0K -$2.600M
YoY Change -41.74% -110.93% -768.14%
Depreciation, Depletion And Amortization $2.760K $1.780K $1.781K
YoY Change 61.78% 57.52% 145.99%
Cash From Operating Activities -$1.544M -$1.421M -$1.322M
YoY Change 8.75% -9.47% 20.65%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00 $0.00
YoY Change -100.0% -100.0% -100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 $0.00 $0.00
YoY Change -100.0% -100.0% -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.770M 0.000 $32.40K
YoY Change -38.99% -48.89%
NET CHANGE
Cash From Operating Activities -1.544M -1.421M -$1.322M
Cash From Investing Activities 0.000 0.000 $0.00
Cash From Financing Activities 2.770M 0.000 $32.40K
Net Change In Cash 1.226M -1.421M -$1.290M
YoY Change -60.59% -10.04% 24.5%
FREE CASH FLOW
Cash From Operating Activities -$1.544M -$1.421M -$1.322M
Capital Expenditures $0.00 $0.00 $0.00
Free Cash Flow -$1.544M -$1.421M -$1.322M
YoY Change 9.52% -8.89% 20.27%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px;"><div style="color: rgb(0, 0, 0); font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-decoration:underline;display:inline;">Use of Estimates</div></div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px; background: none;"><div style="color: rgb(0, 0, 0); font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px;"><div style="color: rgb(0, 0, 0); font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px;"><div style="color: rgb(0, 0, 0); font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-decoration:underline;display:inline;">Concentration of Credit Risk</div></div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px; background: none;"><div style="color: rgb(0, 0, 0); font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px;"><div style="color: rgb(0, 0, 0); font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash. The Company maintains its cash in bank deposits accounts, which, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts. The Company believes it is not exposed to any significant credit risk on cash.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2019Q1 us-gaap Cash
Cash
1956260
CY2018Q3 us-gaap Cash
Cash
4667410
CY2019Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
453072
CY2018Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
151794
CY2019Q1 us-gaap Assets Current
AssetsCurrent
2409332
CY2018Q3 us-gaap Assets Current
AssetsCurrent
4819204
CY2019Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
13700
CY2018Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
17261
CY2019Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3500
CY2018Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3500
CY2019Q1 us-gaap Assets Noncurrent
AssetsNoncurrent
17200
us-gaap Derivatives Reporting Of Derivative Activity
DerivativesReportingOfDerivativeActivity
<div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px;"><div style="color: rgb(0, 0, 0); font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-decoration:underline;display:inline;">Derivative Liabilities</div></div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px; background: none;"><div style="color: rgb(0, 0, 0); font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px;"><div style="color: rgb(0, 0, 0); font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company accounts for its warrants and other derivative financial instruments as either equity or liabilities based upon the characteristics and provisions of each instrument, in accordance with FASB ASC Topic 815, </div><div style="color: rgb(0, 0, 0); font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Derivatives and Hedging</div></div><div style="color: rgb(0, 0, 0); font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. Warrants classified as equity are recorded at fair value as of the date of issuance on the Company&#8217;s consolidated balance sheets and no further adjustments to their valuation are made. Warrants classified as derivative liabilities and other derivative financial instruments that require separate accounting as liabilities are recorded on the Company&#8217;s consolidated balance sheets at their fair value on the date of issuance and will be revalued on each subsequent balance sheet date until such instruments are exercised or expire, with any changes in the fair value between reporting periods recorded as other income or expense. Management estimates the fair value of these liabilities using option pricing models and assumptions that are based on the individual characteristics of the warrants or instruments on the valuation date, as well as assumptions for expected volatility, expected life, yield, and risk-free interest rate.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2018Q3 us-gaap Assets Noncurrent
AssetsNoncurrent
20761
CY2019Q1 us-gaap Assets
Assets
2426532
CY2018Q3 us-gaap Assets
Assets
4839965
CY2019Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
175604
CY2018Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
160946
CY2019Q1 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
105024
CY2018Q3 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
127439
CY2019Q1 us-gaap Liabilities Current
LiabilitiesCurrent
280628
CY2018Q3 us-gaap Liabilities Current
LiabilitiesCurrent
288385
CY2019Q1 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
2346837
CY2018Q3 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
3191752
CY2019Q1 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
2346837
CY2018Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
3191752
CY2019Q1 us-gaap Liabilities
Liabilities
2627465
CY2018Q3 us-gaap Liabilities
Liabilities
3480137
CY2019Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q1 us-gaap Common Stock Value
CommonStockValue
163947
CY2018Q3 us-gaap Common Stock Value
CommonStockValue
159815
CY2019Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
36382873
CY2018Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
35517491
CY2019Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-36747753
CY2018Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-34317478
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
-200933
CY2018Q3 us-gaap Stockholders Equity
StockholdersEquity
1359828
CY2019Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2426532
CY2018Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
4839965
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2019Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
28026
CY2018Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
28026
CY2019Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Excluding Capital Leased Assets
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentExcludingCapitalLeasedAssets
14326
CY2018Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Excluding Capital Leased Assets
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentExcludingCapitalLeasedAssets
10765
CY2019Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
13700
CY2018Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
17261
CY2019Q1 us-gaap Depreciation
Depreciation
1780
CY2018Q1 us-gaap Depreciation
Depreciation
1130
us-gaap Depreciation
Depreciation
3561
us-gaap Depreciation
Depreciation
1854
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
15684210
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1525000
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
1525000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
104212
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
15579998
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.40
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P3Y10M20D
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1142521
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.40
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.37
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0.37
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.40
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P3Y6M
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
833200
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
12633026
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
0.39
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P3Y11M4D
CY2019Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
809807
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
15579998
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
0.40
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P3Y6M
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
833200
CY2019Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2019Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
164961849
CY2018Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
164297013
CY2018Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2018Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
164297013
CY2019Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
164961849
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.9300
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.1944
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0138
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0323
arth Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Forfeiture Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate
0.0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y9M
CY2019Q1 us-gaap Revenues
Revenues
0
CY2018Q1 us-gaap Revenues
Revenues
0
CY2017Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage
SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
1.00
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
100000
CY2019Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
878610
CY2018Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
999388
CY2019Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
628756
CY2018Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1014457
CY2019Q1 us-gaap Operating Expenses
OperatingExpenses
1507366
CY2018Q1 us-gaap Operating Expenses
OperatingExpenses
2013845
CY2019Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-1507366
CY2018Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2013845
CY2019Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
1677328
CY2018Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
458484
CY2019Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
1677328
CY2018Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
458484
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
169962
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-1555361
us-gaap Revenues
Revenues
0
us-gaap Revenues
Revenues
0
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2057233
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2000899
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1217957
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1595319
us-gaap Operating Expenses
OperatingExpenses
3275190
us-gaap Operating Expenses
OperatingExpenses
3596218
us-gaap Operating Income Loss
OperatingIncomeLoss
-3275190
us-gaap Operating Income Loss
OperatingIncomeLoss
-3596218
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
844915
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
2430033
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
844915
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
2430033
us-gaap Net Income Loss
NetIncomeLoss
-2430275
us-gaap Net Income Loss
NetIncomeLoss
-1166185
CY2019Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0
CY2018Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2019Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
163285738
CY2018Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
150302013
CY2019Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0
CY2018Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
CY2019Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
168620980
CY2018Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
150302013
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
162159275
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
150222429
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
162159275
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
150222429
us-gaap Depreciation
Depreciation
3561
us-gaap Depreciation
Depreciation
1854
us-gaap Share Based Compensation
ShareBasedCompensation
815614
us-gaap Share Based Compensation
ShareBasedCompensation
950884
us-gaap Increase Decrease In Restricted Cash For Operating Activities
IncreaseDecreaseInRestrictedCashForOperatingActivities
-21500
us-gaap Increase Decrease In Restricted Cash For Operating Activities
IncreaseDecreaseInRestrictedCashForOperatingActivities
0
us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
-844915
us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
-2430033
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
301278
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-15486
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
14658
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
52618
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-22415
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-94172
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2743550
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2669548
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
9894
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-9894
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
63388
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
32400
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
32400
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
63388
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-2711150
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-2616054
CY2018Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4667410
CY2017Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5994052
CY2019Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1956260
CY2018Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3377998
us-gaap Stock Issued1
StockIssued1
477
us-gaap Stock Issued1
StockIssued1
117
arth Stock Issued During Period Value Restricted Stock Vested
StockIssuedDuringPeriodValueRestrictedStockVested
3567
arth Stock Issued During Period Value Restricted Stock Vested
StockIssuedDuringPeriodValueRestrictedStockVested
0
CY2018Q2 us-gaap Derivative Liabilities
DerivativeLiabilities
2397454
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
3113903
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-1555361
CY2018Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
516064
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
-664072
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
169962
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
293177
CY2017Q3 us-gaap Stockholders Equity
StockholdersEquity
2226519
us-gaap Net Income Loss
NetIncomeLoss
-1166185
arth Stock Issued During Period Value Warants Exercised
StockIssuedDuringPeriodValueWarantsExercised
63388
arth Stock Issued During Period Value Cash Less Stock Options Exercised Two
StockIssuedDuringPeriodValueCashLessStockOptionsExercisedTwo
0
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
950884
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
2074606
CY2018Q3 us-gaap Stockholders Equity
StockholdersEquity
1359828
us-gaap Net Income Loss
NetIncomeLoss
-2430275
arth Stock Issued During Period Value Cash Less Stock Options Exercised One
StockIssuedDuringPeriodValueCashLessStockOptionsExercisedOne
32400
arth Stock Issued During Period Value Cash Less Stock Options Exercised Two
StockIssuedDuringPeriodValueCashLessStockOptionsExercisedTwo
0
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
815614
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
-200933
CY2019Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0
arth Stock Issued During Period Value Restricted Stock For Services
StockIssuedDuringPeriodValueRestrictedStockForServices
21500
us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0
dei Document Type
DocumentType
10-Q
dei Amendment Flag
AmendmentFlag
false
dei Document Period End Date
DocumentPeriodEndDate
2019-03-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2019
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Registrant Name
EntityRegistrantName
Arch Therapeutics, Inc.
dei Entity Central Index Key
EntityCentralIndexKey
0001537561
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--09-30
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Trading Symbol
TradingSymbol
ARTH
CY2019Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
173577233
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Small Business
EntitySmallBusiness
true

Files In Submission

Name View Source Status
0001144204-19-025993-index-headers.html Edgar Link pending
0001144204-19-025993-index.html Edgar Link pending
0001144204-19-025993.txt Edgar Link pending
0001144204-19-025993-xbrl.zip Edgar Link pending
arth-20190331.xml Edgar Link completed
arth-20190331.xsd Edgar Link pending
arth-20190331_cal.xml Edgar Link unprocessable
arth-20190331_def.xml Edgar Link unprocessable
arth-20190331_lab.xml Edgar Link unprocessable
arth-20190331_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tv519163_10q.htm Edgar Link pending
tv519163_ex31-1.htm Edgar Link pending
tv519163_ex31-2.htm Edgar Link pending
tv519163_ex32-1.htm Edgar Link pending